Skip to main content
F

Formosa Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 6838 TW Professional, scientific and technical activities
Open in API
Filings indexed 23 across all filing types
Latest filing 2026-04-17 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 6838

About Formosa Pharmaceuticals, Inc.

https://www.formosapharma.com

Formosa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies within the fields of ophthalmology, oncology, and anti-infectives. The company utilizes its proprietary Activus Pure Nano-technology (APNT®) platform to enhance the formulation of poorly soluble drugs, improving bioavailability and efficacy. Its lead product, APP13007, is a clobetasol propionate ophthalmic suspension developed for the treatment of post-operative inflammation and pain following ocular surgery, which has received regulatory approval in the United States. Formosa Pharmaceuticals focuses on the 505(b)(2) regulatory pathway and the development of antibody-drug conjugates (ADCs). The company actively pursues global licensing and co-development partnerships to advance its pipeline of high-value therapeutic assets.

Recent filings

Filing Released Lang Actions
114年第4季財務報告書 — 202502_6838_AIA.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report titled 'Consolidated Financial Statements and Independent Auditors' Review Report' for Formosa Pharmaceuticals, Inc. for the six-month period ended June 30, 2025. It includes a balance sheet, income statement, statement of changes in equity, and detailed notes to the financial statements. As it covers a period shorter than a full fiscal year and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2025
2026-04-17 English
114年第4季財務報告書 — 202502_6838_AI1.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the second quarter of 114 (2025) for '台新藥股份有限公司' (Formosa Pharmaceuticals, Inc.). It includes a cover page, a table of contents, an independent auditor's review report, consolidated balance sheets, consolidated statements of comprehensive income, consolidated statements of changes in equity, consolidated statements of cash flows, and detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it contains substantive financial statements and analysis for a period shorter than a full fiscal year. Q2 2025
2026-04-17 Chinese
114年第4季財務報告書 — 202501_6838_AIA.pdf
Regulatory Filings
2026-04-17 Chinese
114年第4季財務報告書 — 202501_6838_AI1.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a 'Consolidated Financial Report' (合併財務報告) for the first quarter of 114 and 113 (民國114年及113年第一季) for 'TaiGen Biotechnology Co., Ltd.' (台新藥股份有限公司). It includes a balance sheet, statement of comprehensive income, statement of changes in equity, statement of cash flows, and detailed notes to the financial statements, all accompanied by an independent auditor's review report (會計師核閱報告). This document contains substantive financial data and analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2026-04-17 Chinese
(調整召集事由) 公告本公司董事會決議召開115年股東常會相關事宜
AGM Information Classification · 1% confidence The document is an official announcement by the company’s board of directors resolving to convene the annual shareholders’ meeting, listing the meeting date, venue, and detailed agenda items (reports, approvals, discussion items). This fits the category of materials and notices related to the Annual General Meeting (AGM). Hence it should be classified as AGM Information (AGM-R).
2026-04-13 Chinese
115年03月內部人持股異動(事後)
Regulatory Filings Classification · 0% confidence The provided text is clearly an access error page with no substantive financial or corporate filing content. It does not match any specific filing category definitions and thus defaults to the fallback category for miscellaneous regulatory announcements.
2026-04-07 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.